References
- Jabbour EJ, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 2016;91:252-65
- National Comprehensive Cancer Network Guidelines. Chronic myeloid leukemia, v. I, 2016. Fort Washington, PA: NCCN
- Jabbour EJ, Hughes TP, Cortés JE, et al. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma 2014;55:1451-62
- Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol 2007;44:S4-S14
- Jabbour EJ, Cortés J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 2009;4:3-10
- Jabbour EJ, Cortés JE, Kantarjian H. Long-term outcomes in the second-line treatment of chronic myeloid leukemia. Cancer 2011;117:897-906
- Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, et al. Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency. J Manag Care Spec Pharm 2017;23:214-24
- Knopf KB, Divino V, McGarry L, et al. Economic burden of tyrosine kinase inhibitor treatment failure in chronic myeloid leukemia. Clin Lymphoma Meyeloma Leuk 2015;15:e163-71
- McGarry LJ, Chen YJ, Divino V, et al. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Curr Med Res Opin 2016;32:289-99